Nothing Special   »   [go: up one dir, main page]

WO1990004353A2 - Procede non invasif de determination intermittente et/ou continue du taux d'hemoglobine, d'oxygene arteriel et l'hematocrite - Google Patents

Procede non invasif de determination intermittente et/ou continue du taux d'hemoglobine, d'oxygene arteriel et l'hematocrite Download PDF

Info

Publication number
WO1990004353A2
WO1990004353A2 PCT/US1989/004846 US8904846W WO9004353A2 WO 1990004353 A2 WO1990004353 A2 WO 1990004353A2 US 8904846 W US8904846 W US 8904846W WO 9004353 A2 WO9004353 A2 WO 9004353A2
Authority
WO
WIPO (PCT)
Prior art keywords
changes
volume
hemoglobin
measured
volume change
Prior art date
Application number
PCT/US1989/004846
Other languages
English (en)
Other versions
WO1990004353A3 (fr
Inventor
Dietrich Gravenstein
J. E. W. Beneken
Samsun Lampotang
Nikolaus Gravenstein
Michael A. Brooks
Gordon L. Gibby
Robert J. Atwater
Original Assignee
Dietrich Gravenstein
Beneken J E W
Samsun Lampotang
Nikolaus Gravenstein
Brooks Michael A
Gibby Gordon L
Atwater Robert J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dietrich Gravenstein, Beneken J E W, Samsun Lampotang, Nikolaus Gravenstein, Brooks Michael A, Gibby Gordon L, Atwater Robert J filed Critical Dietrich Gravenstein
Priority to EP89913020A priority Critical patent/EP0440745B1/fr
Priority to DE68927614T priority patent/DE68927614T2/de
Publication of WO1990004353A2 publication Critical patent/WO1990004353A2/fr
Publication of WO1990004353A3 publication Critical patent/WO1990004353A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14535—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring haematocrit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/417—Evaluating particular organs or parts of the immune or lymphatic systems the bone marrow

Definitions

  • ICU intensive care unit
  • ER emergency room
  • OR operating room
  • RR recovery room
  • Pulse oximeter design is well documented. It utilizes two light-emitting diodes (LED). Each LED emits a specific wavelength of light that is transmitted through the tissues to a photodetector. These wavelengths are chosen to be around 660 nm (red spectrum) and around 940 nm (near-infrared spectrum) because of the absorbency characteristics of oxyhemoglobin (Hb02) and reduced hemoglobin (RHb).
  • An electrical signal consisting of two components is generated by the photodetector receiving the LED emission. There is an invariant direct current (DC) component to the signal which represents ambient background light .and transmission of light through invariant, that is, nonpulsatile tissues such as skin, bone, and, to a certain extent, veins.
  • DC direct current
  • the second component of the signal is an alternating current (AC) which represents the varying transmission of light through the pulse-varying tissues, i.e., the arteries and capillaries.
  • AC alternating current
  • Both the AC and DC components are affected by altered LED light intensity.
  • the AC signals must be corrected for inter-LED light intensity differences prior to their use for Sp02 calculation.
  • a pulse oximeter does this by dividing each LED's AC signal by its corresponding DC signal to produce the "corrected AC signal.”
  • the ratio of the corrected AC signal at 660 nm to that at 940 nm is compared to a stored calibration curve that yields Sp02.
  • a pulse oximeter generates a corrected AC signal for both LED wavelengths.
  • the subject invention concerns a novel means and device for noninvasive determination of total hemoglobin, arterial oxygen content, and hematocrit.
  • these dete ⁇ ninations can be made intermittently and/or continuously.
  • the novel procedure described here is painless and eliminates the need for skin punctures. It is cost effective because there is no need for needles, syringes, gloves, bandages or skilled technicians.
  • critical data can be obtained in seconds rather than minutes or hours.
  • the determination of the blood parameters of interest is accomplished by measuring the change in the mass of hemoglobin (Hb02, RHb, or THb) resulting from a measured change in volume of blood.
  • Hb02, RHb, or THb The change in the mass of hemoglobin species can be measured photometrically by passing light of appropriate wavelength(s) through a portion of the body.
  • the attenuation of the light which can be detected by a photometer is related to the amount of hemoglobin species in the blood being analyzed.
  • changes occur in the volume or hemoglobin species concentration of blood being analyzed corresponding changes in the mass of hemoglobin species can be measured.
  • Figure 1 is a schematic representation of one embodiment of the invention where Hb02 is measured directly and a pulse oximeter is utilized.
  • Figure 2 is a schematic representation of one embodiment of the invention where Hb02 is measured directly and a pulse oximeter is not explicitly incorporated.
  • FIG. 3 is a schematic representation of one embodiment of the invention where THb is measured directly and a pulse oximeter is not explicitly incorporated.
  • Figure 4 is a schematic representation of one embodiment of the invention where desired hemoglobin species is/are measured and a pulse oximeter is not explicitly incorporated.
  • Oxyhemoglobin (Hb02) is the oxygen carrying species of THb and can be calculated
  • oxygen content can be calculated if oxyhemoglobin is known. Therefore, if the mass of oxyhemoglobin molecules [mHb02(g)] in a given volume [V(dl)] is known, the oxygen content of that volume can be determined. Stated another way, if a change in the mHb02 can be measured along with the corresponding change in volume, oxygen content can be measured. This relationship can be written
  • Hb02(g/dl) [mHb02, 2 - mHb02 tl ]/[V t2 - V tl ], (4)
  • Hb02 ⁇ mHb02/ ⁇ V, (5)
  • ⁇ mHb02 is the change in mass of the Hb02 species and ⁇ V is the measured corresponding change in volume.
  • the value for ⁇ mHb02, if mHb02 is measured directly, can be calculated using a signal generated by a pulse oximeter, for example.
  • mHb02 can also be determined indirectly. Indirect determination requires accurate Sp02 and either RHb or THb values. Sa02 and Sp02 are known to be close to each other. If RHb and Sp02 are known, then
  • Hb02 THb-RHb, (8) one obtains:
  • Hb02 [(RHb x 100)/(100-SpO2)]-RHb. (9)
  • Equation (2) can be utilized for indirect mHb02 determination.
  • Equations (4) and (5) These equations are clinically useful approximations of the pertinent biological phenomena to be measured by the subject invention. Additional terms can be added to Equations (4) and (5). These additional terms reflect the relatively small effects which are attributable to respiration and other physiological activities. These effects can be extracted and utilized for analysis of respiration and other clinically-relevant parameters.
  • Ca02 is calculated in real-time by one of several similar algorithms entirely through noninvasive means. If the algorithm solving directly for
  • THb can be calculated using the Sp02 output from another device, such as the pulse oximeter, with the equation
  • RBC red blood cell
  • the claimed device -comprises a small appliance that is easily attached to the patient.
  • the device can be attached onto the finger, earlobe, wrist, lips, nares, tongue, cheek, or some other site.
  • the device further comprises a signal processing part that displays the results. The device displays
  • Hct Ca02, Hb, and an estimate of Hct continuously or intermittently.
  • MetHb, and COHb can also be quantified.
  • the device does not necessarily require incorporation into a pulse oximeter, or similar device, to determine THb. Instead, an Sp02 value can be obtained via the digital output port of a pulse oximeter, or similar device, and input into the proposed device. Thus, the device could be incorporated into a pulse oximeter (or similar device), as illustrated in Figure 1, or operate as a unit distinct from it as diagrammed in Figures 2, 3 and 4.
  • the invention claimed here can be practiced with only one light source and a means of ⁇ V determination. Access to Sp ⁇ 2 output (obtained from any accurate source, such as a pulse oximeter) is required to calculate either THb and Hct, or Ca02, depending upon the algorithm chosen.
  • the novel device can be built into a pulse oximeter; no additional light source is required.
  • the component that determines ⁇ V is also supplied. The measurement of changes in mHb02 is then correlated to volume changes that are either passively measured or actively produced.
  • Changes in the mass of oxyhemoglobin, total hemoglobin, and reduced hemoglobin molecules can be measured via absorption photometry using light having a wavelength from between about 400 nm and about 1100 nm.
  • a wavelength of about 660 nm can be used for direct Hb02 measurement ( Figure 2).
  • Other wavelengths which can be utilized include 810 nm (direct THb determination, see Figure 3) and 940 nm (direct RHb measurement). These wavelengths of light are sensitive to changes in mHb02j mTHb, and mRHb, respectively.
  • the corrected AC signal can be extracted from a standard pulse oximeter. Alternatively, such a corrected AC signal could be readily obtained by a person skilled in the art utilizing standard equipment and photometric procedures. However, correction of the AC signal is not necessary in all applications.
  • AC or DC signal can be used in the algorithm where THb is measured directly ( Figure 4) using 810 nm light.
  • the desired DC or AC signal is then used to calculate ⁇ mHb02.
  • mHb02 is measured directly, for example, this can be done by generating a calibration curve which relates change of mHb02 to changes in
  • ⁇ mHb02 can be dete ⁇ nined indirectly with the DC signal from an 810 nm light source.
  • THb is measured directly and with Sp02, ⁇ mHb02 is then calculated using equation (2).
  • pulse oximeters which are capable of supplying the desired AC and/or DC signal. Additionally, these devices can be used to obtain accurate Sp02 input values. For example, the Nellcor N-100 (Nellcor, Inc., Hayward, CA) and Ohmeda 3700 (Ohmeda, Boulder, CO) pulse oximeters are accurate to within 1% of their displayed saturations (Cecil, W.T., K . Thorpe, E.E.
  • any type of energy which can be measured and used to quantitate blood constituents may be used to practice the subject invention.
  • any form of electromagnetic radiation, sound wave, or magnetic property which can be used to trans-irradiate a body part can be utilized so long as the characteristics of the energy are altered by the relevant blood constituents and so long as these changes can be measured and correlated with changes in blood volume.
  • the energy be externally supplied.
  • the energy be externally supplied.
  • the invention By measuring energetic and/or magnetic properties emitted from the tissue itself, it is possible to practice the invention. For example, by analyzing the magnetic properties attributable to -the iron associated with hemoglobin and correlating these properties with changes in the blood volume, the relevant blood constituents can theoretically be quantified.
  • NIBP noninvasive blood pressure
  • This commercially available device rapidly pressurizes and depressurizes the bladder to maintain the finger surrounded by the bladder at nearly constant volume during the pulse.
  • the pressure changes in the bladder can be correlated to volume changes in the finger utilizing standard gas law calculations. These calculations take into account original bladder volume, gas temperature, change in bladder volume and compliance of the bladder.
  • a second approach for deterrnining volume changes is to measure changes in the length of the hght path between the light source and photodetector. Then the volume is approximated by modelling the hght path.
  • this model can be a cylinder between emitter and detector with a cross-sectional area equal to the receptive field of the photodetector.
  • Sonomicrometers strain gauges, Hall-effect transducers, optical interferometiy, and electromagnetic field changes can all be utilized to measure small changes in length. Light intensity itself and light phase changes can also be used to measure distance changes.
  • Example 7 Measurements or changes in volume can be made passively or actively.
  • Passive measurement would mvolve, for example, measuring the actual finger expansion and contraction with each pulse. We have been able to show that finger volume does change with each pulse.
  • the finger was placed into a closed rigid chamber (syringe plunger port) filled with an incompressible fluid (water).
  • a pressure transducer Datascope P3 Module interfaced with a Datascope 870
  • Measurement of actively produced volume changes can also be utilized. Active measurement results from compression and release of tissue at the measurement site by a known distance. If the light source and the photodetector are brought closer together by an external force, e.g., a motor, which produces a volume change in the receptive field, the same data can be obtained. This method requires some amount of Hb02 to be displaced from the receptive field. This procedure can result in the measurement of larger changes in volume compared to passive measurements of volume change during a pulse. Measuring larger volume changes can advantageously reduce experimental error during measurement.
  • the device and method of the subject invention can be utilized in conjunction with life support systems and other medical instrumentations.
  • the subject invention can be used as a sensor for a continuous automatic feedback loop that is designed to maintain Ca02 and/or Hb or Hct.
  • An infusion pump, ventilator, and/or anesthesia machine can be controlled by the sensor.
  • the sensor would enable the system to maintain levels of Ca02 and/or Hb/Hct at levels which are predetermined by the operator of the system.
  • Example 10 The wavelength and source of light employed in the design of the invention can be optimized by those skilled in the art, depending on the particular application. Thus, if direct mHb02 determination is desired, an approximately 660 nm hght source can be utilized. If, however, direct mTHb determination is desired, a wavelength near the isobestic point of 805 nm (e.g., 810 nm) can be employed. If direct determination of RHb is sought, a hght wavelength near 940 nm can be used. With any of these wavelengths, the remaining unknown parameters (THb and/or Hct and/or RHb and/or Ca02) can be determined indirectly with the addition of an accurate Sp02 value using the various formulae discussed above.
  • THb and/or Hct and/or RHb and/or Ca02 the remaining unknown parameters
  • the light can be from an LED and/or laser source, such as a laser diode.
  • the laser offers advantages over an LED because its emission spectra is much narrower, its power attenuation with increasing distance is small in comparison, its output is more directional and it is a more ideal beam. Thus, reproducibility and confidence are improved. These advantages allow for easier modeling and subsequent implementation of applications where the distance between hght source and receiver changes. If a laser source is utilized, the use of fiber-optic technology may also be employed. Fiber-optic cables allow the somewhat motion-, temperature-, and current-sensitive laser and detector elements to remain protected and remote from the patient, and also provide an extremely high degree of electrical isolation between the patient and the device.
  • Noise consists of the background hght that enters the photovoltaic cell (PVC) and alters the signal output.
  • Polarizing films can be employed to reduce the effects of background scattered hght. This is achieved by placing a polarizing film in a known orientation between the emitter and tissue and another film in an identical orientation between the tissue and receiver. This configuration prevents randomly polarized hght from entering the PVC. As a consequence, scattered hght from the emitter, as well as ambient hght that is rotated with respect to the orientation of the polarizing films, is filtered from the PVC input. All photoplethysmographic devices, including pulse oximeters, would benefit from this application.
  • polarizing films in this fashion has the added advantage of essentially defining a volume of tissues of similar cross-sectional area to the PVC.
  • the volume's length is the linear distance between emitter and detector. Hence, volume determination is simplified.
  • “Active" volume determination requires a physical displacement of the emitter relative to the PVC. This displacement can be mechanically limited to a known distance. It can also be limited by the tissue pressure upon one of the device elements (i.e., the PVC or hght source), or by a combination of pressure and displacement.
  • Example 13 ight near the isobestic point of Hb02 and RHb (e.g., 810 nm) is absorbed essentially equally well by both species. Therefore, an AC signal representative of pulsatile arterial blood and a DC signal representative of both arterial and venous blood can be obtained. Since arterial and venous THb are the same, either the AC or DC signal can be utilized to determine THb. Input of Sp02 (which reflects arterial oxygen saturation) then allows arterial oxygen content (Ca02) to be calculated. If a DC signal is also obtained at 660 nm, a total (i.e., combined) arterial and venous oxygen content (Cav02) can be determined. Venous 02 content (Cv02) can then be calculated by subtracting
  • Example 14 The method of actively varying volume can be applied equally well to the new pulse oximeter technologies that employ reflectance or backscatter of hght for their signals. If one varied the slab length, width, or depth from which they receive their signals, essentially a volume change would have been made and similar algorithms to those described above would apply. Therefore, Sp02, THb, Hb02, RHb, Ca02 and local oxygen consumption could each be deterimined using these new technologies.
  • the claimed device can also be used to determine interstitial fluid content, or state of hydration.
  • Such a device would be beneficial in the clinical assessment of delirium, hypotension, tachycardia, and other medical conditions.
  • critical care settings e.g., emergency rooms
  • chronic care settings e.g., nursing homes.
  • the novel device of the subject invention operates by measuring changes in signal strength that occur after a rapid compression (or decompression) of a tissue.
  • the tissue can be thought of as a two compartment system: the intravascular compartment that contains blood and the interstitial compartment that contains body water.
  • a hydrostatic pressure change is applied. Since the fluid cannot shift instantaneously between compartments, it shifts first within the compartment with the least resistance to flow.
  • the interstitial fluid is impeded from making rapid shifts because it is trapped in tissue planes and held within the interstitial compartment by hydrophilic molecules.
  • the blood within the intravascular compartment is capable of making rapid shifts.
  • blood upon rapid compression, blood would leave the compressed site almost immediately, and only subsequently does the interstitial water begin to leave the compressed region.
  • blood would almost immediately refill the vasculature.
  • the measured signal varies with the mass of absorber (i.e., mass of Hb02, RHb, or THb, depending on the wavelength used) in the hght path. As reasoned above, after rapid (decompression, the signal can be expected to vary in a fashion that is related to hydration status.
  • a backscatter oximeter may be used to determine mixed venous 02 content in the superficial jugular vein while Ca02 is determined at a peripheral site. Such a combination may provide a good solution to the Fick equation for cardiac output.
  • Another example of a new apphcation is to combine the algorithms that directly determine mTHb and mHb02 by the new method and design an entirely new pulse oximeter based on measured vascular volume changes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

Des moyens et un dispositif nouveaux permettent de quantifier de manière non invasive d'importants constituants du sang. On peut déterminer rapidement et facilement le taux d'hémoglobine totale, d'oxygène artériel, l'hématocrite et autres paramètres sans qu'il soit nécessaire de ponctionner la peau ou de procéder à de longues analyses en laboratoire. L'invention permet de mesurer en même temps des changements de volume et de masse de l'oxyhémoglobine, de l'hémoglobine totale ou de l'hémoglobine réduite. Les données obtenues par ces mesures sont utilisées pour quantifier les paramètres d'intérêt.
PCT/US1989/004846 1988-10-28 1989-10-27 Procede non invasif de determination intermittente et/ou continue du taux d'hemoglobine, d'oxygene arteriel et l'hematocrite WO1990004353A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP89913020A EP0440745B1 (fr) 1988-10-28 1989-10-27 Procede non invasif de determination intermittente et/ou continue du taux d'hemoglobine, d'oxygene arteriel et l'hematocrite
DE68927614T DE68927614T2 (de) 1988-10-28 1989-10-27 Verfahren zur nichtinvasiven periodischen und/oder kontinuierlichen Bestimmung von Hämoglobin , arteriellem Sauerstoffgehalt und Hämatokrit

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26411988A 1988-10-28 1988-10-28
US264,119 1988-10-28
US368,636 1989-06-20
US07/368,636 US5101825A (en) 1988-10-28 1989-06-20 Method for noninvasive intermittent and/or continuous hemoglobin, arterial oxygen content, and hematocrit determination

Publications (2)

Publication Number Publication Date
WO1990004353A2 true WO1990004353A2 (fr) 1990-05-03
WO1990004353A3 WO1990004353A3 (fr) 1990-08-23

Family

ID=26950268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/004846 WO1990004353A2 (fr) 1988-10-28 1989-10-27 Procede non invasif de determination intermittente et/ou continue du taux d'hemoglobine, d'oxygene arteriel et l'hematocrite

Country Status (7)

Country Link
US (1) US5101825A (fr)
EP (1) EP0440745B1 (fr)
AT (1) ATE146952T1 (fr)
AU (1) AU4636089A (fr)
CA (1) CA2001455A1 (fr)
DE (1) DE68927614T2 (fr)
WO (1) WO1990004353A2 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011701A1 (fr) * 1991-12-12 1993-06-24 Vivascan Corporation Mesure non invasive de la teneur en hematocryte et hemoglobine par analyse optique differentielle______________________
EP0555553A2 (fr) * 1992-02-07 1993-08-18 BOC Health Care, Inc. Système amélioré de surveillance du sang artériel
US5297548A (en) * 1992-02-07 1994-03-29 Ohmeda Inc. Arterial blood monitoring probe
WO1996039926A1 (fr) * 1995-06-07 1996-12-19 Masimo Corporation Controle de constituants du sang par impulsions actives
WO1996039927A1 (fr) * 1995-06-07 1996-12-19 Blackbox, Inc. Procede pour la mesure non invasive, intermittente et/ou continue de l'hemoglobine, de la teneur en oxygene arteriel, et de l'hematocrite
US5706208A (en) * 1989-09-18 1998-01-06 Minnesota Mining And Manufacturing Company Method for the prediction of properties of biological matter by analysis of the near-infrared spectrum thereof
US5729333A (en) * 1989-09-18 1998-03-17 Minnesota Mining And Manufacturing Company Characterizing biological matter in a dynamic condition using near infrared spectroscopy spectrum
WO1998025514A1 (fr) * 1996-12-11 1998-06-18 Alliance Pharmaceutical Corp. Systeme et procedes de mesure de parametres d'oxygenation
US6743172B1 (en) 1998-01-14 2004-06-01 Alliance Pharmaceutical Corp. System and method for displaying medical process diagrams
US6860266B2 (en) 2000-11-03 2005-03-01 Dartmouth-Hitchcock Clinic Physiological object displays
US6931268B1 (en) 1995-06-07 2005-08-16 Masimo Laboratories, Inc. Active pulse blood constituent monitoring
US7003337B2 (en) 2002-04-26 2006-02-21 Vivascan Corporation Non-invasive substance concentration measurement using and optical bridge
US8175666B2 (en) 2002-04-26 2012-05-08 Grove Instruments, Inc. Three diode optical bridge system
US9442065B2 (en) 2014-09-29 2016-09-13 Zyomed Corp. Systems and methods for synthesis of zyotons for use in collision computing for noninvasive blood glucose and other measurements
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5291895A (en) * 1985-06-03 1994-03-08 Mcintyre Kevin M Evaluation of heart mechanical performance
US5526808A (en) * 1990-10-04 1996-06-18 Microcor, Inc. Method and apparatus for noninvasively determining hematocrit
US5642734A (en) * 1990-10-04 1997-07-01 Microcor, Inc. Method and apparatus for noninvasively determining hematocrit
US5372136A (en) * 1990-10-06 1994-12-13 Noninvasive Medical Technology Corporation System and method for noninvasive hematocrit monitoring
US6266546B1 (en) 1990-10-06 2001-07-24 In-Line Diagnostics Corporation System for noninvasive hematocrit monitoring
US5351686A (en) * 1990-10-06 1994-10-04 In-Line Diagnostics Corporation Disposable extracorporeal conduit for blood constituent monitoring
US6681128B2 (en) 1990-10-06 2004-01-20 Hema Metrics, Inc. System for noninvasive hematocrit monitoring
US6725072B2 (en) * 1990-10-06 2004-04-20 Hema Metrics, Inc. Sensor for transcutaneous measurement of vascular access blood flow
US6246894B1 (en) 1993-02-01 2001-06-12 In-Line Diagnostics Corporation System and method for measuring blood urea nitrogen, blood osmolarity, plasma free hemoglobin and tissue water content
US5487384A (en) * 1993-02-25 1996-01-30 Blue Marble Research, Inc. Kinematic assay of plasma glucose concentration without blood sampling
JP3260472B2 (ja) * 1993-03-26 2002-02-25 浜松ホトニクス株式会社 診断装置
DE69333456T2 (de) * 1993-04-12 2005-01-27 Hema Metrics, Inc., Riverdale System verfahren zur nichtinvasiven überwachung des hämatocrit-wertes
DE4329898A1 (de) * 1993-09-04 1995-04-06 Marcus Dr Besson Kabelloses medizinisches Diagnose- und Überwachungsgerät
US5553615A (en) * 1994-01-31 1996-09-10 Minnesota Mining And Manufacturing Company Method and apparatus for noninvasive prediction of hematocrit
DE19518511C2 (de) * 1994-05-20 1998-04-02 Hermann Dipl Ing Kuenst Verfahren zur transcutanen, unblutigen In-vivo-Konzentrationsbestimmung von Substanzen im Blut
DE19612425C2 (de) * 1995-03-31 2000-08-31 Nihon Kohden Corp Apparat zur Messung von Hämoglobinkonzentration
US5978691A (en) * 1996-07-19 1999-11-02 Mills; Alexander Knight Device and method for noninvasive continuous determination of blood gases, pH, hemoglobin level, and oxygen content
US6018673A (en) 1996-10-10 2000-01-25 Nellcor Puritan Bennett Incorporated Motion compatible sensor for non-invasive optical blood analysis
US6117099A (en) 1996-10-23 2000-09-12 In-Line Diagnostics Corporation System and method for noninvasive hemodynamic measurements in hemodialysis shunts
US6090061A (en) * 1997-10-22 2000-07-18 In-Line Diagnostics Corporation Disposable extracorporeal conduit for blood constituent monitoring
US6746415B1 (en) * 1996-10-23 2004-06-08 Hema Metrics, Inc. Method of blood constituent monitoring using improved disposable extracorporeal conduit
US6826422B1 (en) 1997-01-13 2004-11-30 Medispectra, Inc. Spectral volume microprobe arrays
US6847490B1 (en) 1997-01-13 2005-01-25 Medispectra, Inc. Optical probe accessory device for use in vivo diagnostic procedures
US6804543B2 (en) 1998-02-05 2004-10-12 Hema Metrics, Inc. Sensor for transcutaneous measurement of vascular access blood flow
US6694157B1 (en) 1998-02-10 2004-02-17 Daedalus I , L.L.C. Method and apparatus for determination of pH pCO2, hemoglobin, and hemoglobin oxygen saturation
US6009340A (en) * 1998-03-16 1999-12-28 Northrop Grumman Corporation Multimode, multispectral imaging system
US6064898A (en) * 1998-09-21 2000-05-16 Essential Medical Devices Non-invasive blood component analyzer
JP2000155090A (ja) * 1998-11-20 2000-06-06 Fuji Photo Film Co Ltd 血管の画像化装置
WO2000037917A2 (fr) * 1998-12-23 2000-06-29 Medispectra, Inc. Systemes et procedes d'analyse optique d'echantillons
CA2356195A1 (fr) * 1998-12-23 2000-06-29 Medispectra, Inc. Systemes et techniques optiques destines a l'examen du col
IL129790A0 (en) 1999-03-09 2000-02-29 Orsense Ltd A device for enhancement of blood-related signals
US7187810B2 (en) * 1999-12-15 2007-03-06 Medispectra, Inc. Methods and systems for correcting image misalignment
US7260248B2 (en) * 1999-12-15 2007-08-21 Medispectra, Inc. Image processing using measures of similarity
US20020007122A1 (en) * 1999-12-15 2002-01-17 Howard Kaufman Methods of diagnosing disease
US6839661B2 (en) * 2000-12-15 2005-01-04 Medispectra, Inc. System for normalizing spectra
US6746407B2 (en) 2000-12-29 2004-06-08 Hema Metrics, Inc. Method of measuring transcutaneous access blood flow
US6709402B2 (en) * 2002-02-22 2004-03-23 Datex-Ohmeda, Inc. Apparatus and method for monitoring respiration with a pulse oximeter
US20030212316A1 (en) 2002-05-10 2003-11-13 Leiden Jeffrey M. Method and apparatus for determining blood parameters and vital signs of a patient
US7469160B2 (en) * 2003-04-18 2008-12-23 Banks Perry S Methods and apparatus for evaluating image focus
US6818903B2 (en) 2002-07-09 2004-11-16 Medispectra, Inc. Method and apparatus for identifying spectral artifacts
US7309867B2 (en) * 2003-04-18 2007-12-18 Medispectra, Inc. Methods and apparatus for characterization of tissue samples
US20040208390A1 (en) * 2003-04-18 2004-10-21 Medispectra, Inc. Methods and apparatus for processing image data for use in tissue characterization
US7136518B2 (en) * 2003-04-18 2006-11-14 Medispectra, Inc. Methods and apparatus for displaying diagnostic data
US7459696B2 (en) 2003-04-18 2008-12-02 Schomacker Kevin T Methods and apparatus for calibrating spectral data
US6933154B2 (en) * 2002-07-09 2005-08-23 Medispectra, Inc. Optimal windows for obtaining optical data for characterization of tissue samples
US20040208385A1 (en) * 2003-04-18 2004-10-21 Medispectra, Inc. Methods and apparatus for visually enhancing images
US7282723B2 (en) 2002-07-09 2007-10-16 Medispectra, Inc. Methods and apparatus for processing spectral data for use in tissue characterization
US7103401B2 (en) * 2002-07-10 2006-09-05 Medispectra, Inc. Colonic polyp discrimination by tissue fluorescence and fiberoptic probe
US6768918B2 (en) 2002-07-10 2004-07-27 Medispectra, Inc. Fluorescent fiberoptic probe for tissue health discrimination and method of use thereof
EP1388321A1 (fr) * 2002-08-09 2004-02-11 Instrumentarium Oyj Procédé et systeme de mesure continue et non invasive de la pression sanguine
US8895298B2 (en) 2002-09-27 2014-11-25 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US7011631B2 (en) * 2003-01-21 2006-03-14 Hemonix, Inc. Noninvasive method of measuring blood density and hematocrit
US7254431B2 (en) * 2003-08-28 2007-08-07 Masimo Corporation Physiological parameter tracking system
WO2006094169A1 (fr) 2005-03-01 2006-09-08 Masimo Laboratories, Inc. Emetteurs de capteur a longueurs d'onde multiples
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
US8921102B2 (en) * 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
DE102006052125A1 (de) * 2005-11-15 2007-05-16 Weinmann G Geraete Med Vorrichtung zur Bestimmung physiologischer Variablen
US8543180B2 (en) * 2006-05-03 2013-09-24 Covidien Lp Method and apparatus for total hemoglobin measurement
US9408538B2 (en) * 2006-05-03 2016-08-09 Triple Ring Technologies, Inc. Method and apparatus for pressure sore detection
US8219170B2 (en) * 2006-09-20 2012-07-10 Nellcor Puritan Bennett Llc System and method for practicing spectrophotometry using light emitting nanostructure devices
US7890153B2 (en) 2006-09-28 2011-02-15 Nellcor Puritan Bennett Llc System and method for mitigating interference in pulse oximetry
US8265723B1 (en) 2006-10-12 2012-09-11 Cercacor Laboratories, Inc. Oximeter probe off indicator defining probe off space
US20080200784A1 (en) * 2007-02-16 2008-08-21 Xuefeng Cheng Method and device for measuring parameters of cardiac function
US8918153B2 (en) 2007-02-16 2014-12-23 Mespere Lifesciences Inc. Method and device for measuring parameters of cardiac function
US8374665B2 (en) 2007-04-21 2013-02-12 Cercacor Laboratories, Inc. Tissue profile wellness monitor
FR2939631A1 (fr) * 2008-12-11 2010-06-18 France Etat Procede de determination de la quantite cpo2 (t0) d'oxygene o2 contenu dans le sang et dispositif associe
US20100185084A1 (en) * 2009-01-22 2010-07-22 Siemens Medical Solutions Usa, Inc. Non-invasive Cardiac Characteristic Determination System
US9579039B2 (en) 2011-01-10 2017-02-28 Masimo Corporation Non-invasive intravascular volume index monitor
US9839381B1 (en) 2009-11-24 2017-12-12 Cercacor Laboratories, Inc. Physiological measurement system with automatic wavelength adjustment
US8801613B2 (en) 2009-12-04 2014-08-12 Masimo Corporation Calibration for multi-stage physiological monitors
CA2953600C (fr) * 2011-07-08 2020-01-07 Lifeq Global Limited Assistant personnalise pour l'alimentation et le bien-etre
US20130066173A1 (en) * 2011-09-09 2013-03-14 Nellcor Puritan Bennett Ireland Venous oxygen saturation systems and methods
US9332917B2 (en) 2012-02-22 2016-05-10 Siemens Medical Solutions Usa, Inc. System for non-invasive cardiac output determination
US10398364B2 (en) 2013-02-13 2019-09-03 Mespere Lifesciences Inc. Method and device for measuring venous blood oxygenation
CN106562776A (zh) 2015-10-08 2017-04-19 米斯比尔生命科学公司 用于非侵入性监测中心静脉压的系统
CN108065940A (zh) * 2016-11-11 2018-05-25 杭州兆观传感科技有限公司 带警报的连续血氧饱和度心率监测戒指
WO2018187510A1 (fr) * 2017-04-04 2018-10-11 Cas Medical Systems, Inc. Procédé et appareil de mesure non invasive de l'hémoglobine circulatoire
CN109106376B (zh) * 2018-09-20 2022-04-19 京东方科技集团股份有限公司 一种血液中总血红蛋白浓度的检测方法及装置

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1076323B (de) * 1957-06-18 1960-02-25 Dr Med Stepan Figar Geraet fuer volumetrische Untersuchungen fuer medizinische Zwecke
US4167331A (en) * 1976-12-20 1979-09-11 Hewlett-Packard Company Multi-wavelength incremental absorbence oximeter
US4506626A (en) * 1981-11-02 1985-03-26 Schurman Richard H Apparatus for controlling the proportions of a fluid
US4524777A (en) * 1983-02-25 1985-06-25 Ueda Electronic Works Limited Automatic, continuous and indirect blood pressure measurement apparatus
GB2197499A (en) * 1986-08-25 1988-05-18 Hamamatsu Photonics Kk High spatial and time resolution measuring apparatus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704029A (en) * 1985-12-26 1987-11-03 Research Corporation Blood glucose monitor
US4805623A (en) * 1987-09-04 1989-02-21 Vander Corporation Spectrophotometric method for quantitatively determining the concentration of a dilute component in a light- or other radiation-scattering environment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1076323B (de) * 1957-06-18 1960-02-25 Dr Med Stepan Figar Geraet fuer volumetrische Untersuchungen fuer medizinische Zwecke
US4167331A (en) * 1976-12-20 1979-09-11 Hewlett-Packard Company Multi-wavelength incremental absorbence oximeter
US4506626A (en) * 1981-11-02 1985-03-26 Schurman Richard H Apparatus for controlling the proportions of a fluid
US4524777A (en) * 1983-02-25 1985-06-25 Ueda Electronic Works Limited Automatic, continuous and indirect blood pressure measurement apparatus
GB2197499A (en) * 1986-08-25 1988-05-18 Hamamatsu Photonics Kk High spatial and time resolution measuring apparatus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hewlett-Packard Journal, Volume 28, No. 2, October 1976, (Palo Alto, US), E.B. MERRICK et al.: "Continuous, Non-Invasive Measurements of Arterial Blood Oxygen Levels", pages 2-9 *
IEEE Transactions on Biomedical Engineering, Volume 35, No. 3, March 1988, IEEE, (New York, US), S. TAKATANI et al.: "A Miniature Hybrid Reflection Type Optical Sensor for Measurement of Hemoglobin Content and Oxygen Saturation of whole Blood", pages 187-198 *
Proceedings of the IEEE Seventh Annual Conference of the Engineering in Medicine and Biology Society, 27-30 September 1985, Volume 1, IEEE, (US), T.M. DONAHOE et al.: "A New Noninvasive Backscattering Oximeter", pages 144-147 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5706208A (en) * 1989-09-18 1998-01-06 Minnesota Mining And Manufacturing Company Method for the prediction of properties of biological matter by analysis of the near-infrared spectrum thereof
US5830133A (en) * 1989-09-18 1998-11-03 Minnesota Mining And Manufacturing Company Characterizing biological matter in a dynamic condition using near infrared spectroscopy
US5729333A (en) * 1989-09-18 1998-03-17 Minnesota Mining And Manufacturing Company Characterizing biological matter in a dynamic condition using near infrared spectroscopy spectrum
US5277181A (en) * 1991-12-12 1994-01-11 Vivascan Corporation Noninvasive measurement of hematocrit and hemoglobin content by differential optical analysis
WO1993011701A1 (fr) * 1991-12-12 1993-06-24 Vivascan Corporation Mesure non invasive de la teneur en hematocryte et hemoglobine par analyse optique differentielle______________________
EP0555553A2 (fr) * 1992-02-07 1993-08-18 BOC Health Care, Inc. Système amélioré de surveillance du sang artériel
EP0555553A3 (en) * 1992-02-07 1993-09-08 Boc Health Care, Inc. Improved arterial blood monitoring system
US5297548A (en) * 1992-02-07 1994-03-29 Ohmeda Inc. Arterial blood monitoring probe
US6390977B1 (en) 1995-06-07 2002-05-21 Alliance Pharmaceutical Corp. System and methods for measuring oxygenation parameters
US6931268B1 (en) 1995-06-07 2005-08-16 Masimo Laboratories, Inc. Active pulse blood constituent monitoring
USRE42753E1 (en) 1995-06-07 2011-09-27 Masimo Laboratories, Inc. Active pulse blood constituent monitoring
WO1996039927A1 (fr) * 1995-06-07 1996-12-19 Blackbox, Inc. Procede pour la mesure non invasive, intermittente et/ou continue de l'hemoglobine, de la teneur en oxygene arteriel, et de l'hematocrite
US5860919A (en) * 1995-06-07 1999-01-19 Masimo Corporation Active pulse blood constituent monitoring method
AU712825B2 (en) * 1995-06-07 1999-11-18 Masimo Laboratories, Inc. Active pulse blood constituent monitoring
US6151516A (en) * 1995-06-07 2000-11-21 Masimo Laboratories Active pulse blood constituent monitoring
US5638816A (en) * 1995-06-07 1997-06-17 Masimo Corporation Active pulse blood constituent monitoring
WO1996039926A1 (fr) * 1995-06-07 1996-12-19 Masimo Corporation Controle de constituants du sang par impulsions actives
US6234963B1 (en) 1996-12-11 2001-05-22 Alliance Pharmaceutical Corp. System and method for displaying medical process diagrams
WO1998025514A1 (fr) * 1996-12-11 1998-06-18 Alliance Pharmaceutical Corp. Systeme et procedes de mesure de parametres d'oxygenation
US6743172B1 (en) 1998-01-14 2004-06-01 Alliance Pharmaceutical Corp. System and method for displaying medical process diagrams
US6860266B2 (en) 2000-11-03 2005-03-01 Dartmouth-Hitchcock Clinic Physiological object displays
US7003337B2 (en) 2002-04-26 2006-02-21 Vivascan Corporation Non-invasive substance concentration measurement using and optical bridge
US8175666B2 (en) 2002-04-26 2012-05-08 Grove Instruments, Inc. Three diode optical bridge system
US9442065B2 (en) 2014-09-29 2016-09-13 Zyomed Corp. Systems and methods for synthesis of zyotons for use in collision computing for noninvasive blood glucose and other measurements
US9448164B2 (en) 2014-09-29 2016-09-20 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
US9448165B2 (en) 2014-09-29 2016-09-20 Zyomed Corp. Systems and methods for control of illumination or radiation collection for blood glucose and other analyte detection and measurement using collision computing
US9453794B2 (en) 2014-09-29 2016-09-27 Zyomed Corp. Systems and methods for blood glucose and other analyte detection and measurement using collision computing
US9459202B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for collision computing for detection and noninvasive measurement of blood glucose and other substances and events
US9459203B2 (en) 2014-09-29 2016-10-04 Zyomed, Corp. Systems and methods for generating and using projector curve sets for universal calibration for noninvasive blood glucose and other measurements
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
US9610018B2 (en) 2014-09-29 2017-04-04 Zyomed Corp. Systems and methods for measurement of heart rate and other heart-related characteristics from photoplethysmographic (PPG) signals using collision computing
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing

Also Published As

Publication number Publication date
ATE146952T1 (de) 1997-01-15
AU4636089A (en) 1990-05-14
EP0440745A1 (fr) 1991-08-14
DE68927614T2 (de) 1997-05-28
US5101825A (en) 1992-04-07
WO1990004353A3 (fr) 1990-08-23
DE68927614D1 (de) 1997-02-13
CA2001455A1 (fr) 1990-04-28
EP0440745B1 (fr) 1997-01-02

Similar Documents

Publication Publication Date Title
US5101825A (en) Method for noninvasive intermittent and/or continuous hemoglobin, arterial oxygen content, and hematocrit determination
WO1996039927A1 (fr) Procede pour la mesure non invasive, intermittente et/ou continue de l'hemoglobine, de la teneur en oxygene arteriel, et de l'hematocrite
US10610139B2 (en) Active-pulse blood analysis system
US8078250B2 (en) Method for spectrophotometric blood oxygenation monitoring
US8923942B2 (en) In vivo blood spectrometry
US6456862B2 (en) Method for non-invasive spectrophotometric blood oxygenation monitoring
US7254431B2 (en) Physiological parameter tracking system
US8818472B2 (en) Methods and devices for noninvasive measurement of energy absorbers in blood
WO2000016688A1 (fr) Analyseur non invasif des composants du sang
EP1087693A1 (fr) Mesure optique non-invasive de constituant sanguin
JPH11510722A (ja) 酸素飽和率の測定のための方法、装置及びセンサー
WO2001003577A9 (fr) Procede et dispositif d'oximetrie pulsee a etalonnage adaptatif
US20220412883A1 (en) Method and Apparatus for Non-Invasively Measuring Blood Circulatory Hemoglobin
Reuss et al. The pulse in reflectance pulse oximetry: modeling and experimental studies
Severinghaus History, status and future of pulse oximetry
Suzaki et al. Noninvasive measurement of total hemoglobin and hemoglobin derivatives using multiwavelength pulse spectrophotometry-In vitro study with a mock circulatory system
Vegfors et al. Accuracy of pulse oximetry at various haematocrits and during haemolysis in an in vitro model
Kraitl et al. Non-invasive measurement of blood and tissue parameters based on VIS-NIR spectroscopy
Damianou The wavelength dependence of the photoplethysmogram and its implication to pulse oximetry
Timm et al. Non-invasive continuous online hemoglobin monitoring system
Kumar V et al. Pulse oximetry for the measurement of oxygen saturation in arterial blood
US10863937B2 (en) Ex vivo calibration of a photoplethysmographic device
Yelderman et al. Real time oximetry
Kraitl et al. Optical sensor technology for a noninvasive continuous monitoring of blood components
Abdallah et al. Towards noninvasive monitoring of total hemoglobin concentration and fractional oxygen saturation based on earlobe pulse oximetry

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU DK FI JP SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DK FI JP SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989913020

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989913020

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989913020

Country of ref document: EP